N
Google TrendLIONESS SEASON 3 (5000+) — Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lioness season 35000+luis díaz200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+pope francis500+delaware vs middle tennessee prediction1000+pablo torre500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "How Nonstatin Therapies C" (30 stories)

Top Headline Story

Addressing Elevated LDL-C With Nonstatin Therapies
Lead StoryMedscape Reference: Drugs, Diseases & Medical Proceduresgeneral
Apr 16

Addressing Elevated LDL-C With Nonstatin Therapies

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPWVNiS2RGQmdQWjd5M0JONVpTc2hWWFJOTktBTFd2LWRNbnNPYU15WTNyVkFzQlRweFY5OVVrbG41TzNZTnhXWllZc0g0OEJMNmpvUVdhTlBKcDMyQVZ0bnVVNXQtdGhHNU1CM3NPT1dhZnNnZWRlanlMMUFmckZNVDlWdDRRQml3UDN5TTVKb1lkMHEzaFE?oc=5" target="_blank">Addressing Elevated LDL-C With Nonstatin Therapies</a>  <font color="#6f6f6f">Medscape Reference: Drugs, Diseases & Medical Procedures</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+13m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+23m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories
5000+33m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+33m ago

thélyson orélien

Acclaimed Author Denies Using A.I. but Admits Plagiarism

Filter stories

Search Results for "How Nonstatin Therapies C"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD
HCPLivegeneral

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNV9Gbno1WkhzVEZDZzR3SjkyekxuUHVtZkp6TDVZdmcyc2N0SnJrVl85T0VtSTNjV1JIZDFicGp1SktyVmpzV3I3M0QwSG9ZSmNsQnQ0dmRiSXRUUVRoeVAwMTNaWnl3V3RTMERXRFVtMlFZN1U0bUlzQXByZTFuQnhfZ2UySl9scXl1eHVGS29EUllhcmVKSVFpQnJOYk16MmZDd2hNczE5aGVrMERBRjQ2ZEJPcWVHUHZVbzVKaGE?oc=5" target="_blank">Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 64.6% in Phase 3 Trial vs Nonstatin Therapies
Patient Care Onlinegeneral

Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 64.6% in Phase 3 Trial vs Nonstatin Therapies

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNdUFMdGhpZmlualhUQVcyWUVFTFFfQTNpbVZNMS1nSlBJVUJXMVBGRFhQWENMQ3BoaW1RZkNWMFZZSkw4WThuS1owUVRNb01NMFVOblREQTZfLVAzNHRMdkhLaU1BOXVtVWxqaXdDM1Fvbnh1WlVnd183d1pKWmM3VjBrbXJIVjgxay1GZlFRUFEyS2lMZEFYX05IOEp4VjczU0owaXlhRFRBbGMtUkJqbEZXREwzekNDcmtNZVN5TjlxUTZUck9fTA?oc=5" target="_blank">Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 64.6% in Phase 3 Trial vs Nonstatin Therapies</a>  <font color="#6f6f6f">Patient Care Online</font>

Read Full StoryMore like this
New Oral Contender Outshines Standard Add-on Therapies for LDL-C
Pharmacy Timesgeneral

New Oral Contender Outshines Standard Add-on Therapies for LDL-C

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPM0xYUUxzWi1hNDlmYXk2eGlkSng4SU9DQi1YOTkxd05walZ4Z0xuSmFsVUw4TGFJcXAwUzA2b1lmRmQ5UUpPUmREUXpwa0poNUJNd3huSjJvRlBFOFN4dzhVRWtOUnhCTE5TbW04aGJRUW1xRUNsSzhlRE1aTV9nRTRIc0Z3cmVlZEcxc01oV3ktdDZsb2dpeDFxb3lQS0lR?oc=5" target="_blank">New Oral Contender Outshines Standard Add-on Therapies for LDL-C</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
ACC26: Merck & Co.'s oral PCSK9 yields over 64% LDL-C drop in add-on setting
FirstWord Pharmageneral

ACC26: Merck & Co.'s oral PCSK9 yields over 64% LDL-C drop in add-on setting

<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE43SFo4a3FfMFR5cjA1UktYc3d6ODlNZjRlZUw5SFNMbllXMll3Z013S0NnR3FjUURPRnFnS0E2WHliRjJyVjZRSm5qejFfMVpuSzBr?oc=5" target="_blank">ACC26: Merck & Co.'s oral PCSK9 yields over 64% LDL-C drop in add-on setting</a>  <font color="#6f6f6f">FirstWord Pharma</font>

Read Full StoryMore like this
Oral PCSK9 inhibitor enlicitide cuts LDL-C ~65% on a statin
MDLinxgeneral

Oral PCSK9 inhibitor enlicitide cuts LDL-C ~65% on a statin

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQMHVfWFJmc1luU2k0c29qel95RVZ3VFhKeDBlWGtJQmdKbjVkZmdIUjlTNmR4cDRrMVVPVzlQMTJrWjVCNU1oR19GcHRpWFNHZmdaUThzcG5NbXUyd0Q5eG9vellrbkxJamZlbWozQTVFWWFkX2ZXY1ZnN2NlTjRRUjVYcHJSWnVIcm9FQUxWcjhrMF9UVWo5a05UUV9iZmhVQVNyUW1sSml4NEJwbmVNSg?oc=5" target="_blank">Oral PCSK9 inhibitor enlicitide cuts LDL-C ~65% on a statin</a>  <font color="#6f6f6f">MDLinx</font>

Read Full StoryMore like this
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Business Wireworld

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

<a href="https://news.google.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?oc=5" target="_blank">Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Nonstatin Prescriptions Increasing, Still Behind Statins in ASCVD, With Michael Blaha, MD, MPH
HCPLivegeneral

Nonstatin Prescriptions Increasing, Still Behind Statins in ASCVD, With Michael Blaha, MD, MPH

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYnpTWnYyYndhZ21FMGgwLTVLQmN0bkhndUZRY3lKMFlzYnQ2LVZiSnFGUE1UZjFRZmU2NXBvWERaaUpIY1d6UkJTRzNfRnF4ZGplU2JVLWxLb0h6TlVWVjJJeExBb0VLeXBSU1FFRC10NGxEdFdJRE9SNG00XzgySmVqQVY5M2pyam1RdDcwWDlqY2plMGFyWXh4WUdlalphcjA2cXN0R0swYWRNakJLZDhoS1ZmYWpRVGpB?oc=5" target="_blank">Nonstatin Prescriptions Increasing, Still Behind Statins in ASCVD, With Michael Blaha, MD, MPH</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
LDL-C Targets in Primary vs Secondary Prevention: What Pharmacists Need to Know
Pharmacy Timesgeneral

LDL-C Targets in Primary vs Secondary Prevention: What Pharmacists Need to Know

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPT1JxLThZeUZIOVFKTTNuZ3BzTHBKdlZFU0xRNm9sS2hWMUNnLVFGSldISE5uS1laZFhxVHFXd0ZobERseTlPQ3hEZHh5RHUtYWRVS081dWRWcTBPVVZ5U1piUmlYdnNpN1ZjRW90YTRfTmpOYngyTlh1SDItV282Vl9RdTlTM1VqRFNNMGJpU3VMS2VMbmk2NG53aVhiRzNWWUZtWDhwMmxRRXFHVVkwcnB3WQ?oc=5" target="_blank">LDL-C Targets in Primary vs Secondary Prevention: What Pharmacists Need to Know</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C
The Cardiology Advisorgeneral

ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNeXpwbHh0ZkhyOGJxcTZ2Q3FOWVVXYUFpano3bE9rNElSRnRydzVEODJXWk9pdHRDOWgtTmpqMGFhOXNjLXA2S2NqMmI4N28tVDg0MXZOcFIyS3NfRFB6N0dUVXhJZDRWallsTVY5aUdQdnB1cjEwMHNWb1N4V1NlMU9MZjJmaXFQb1BCRjhDcmJNMzB0cjdTUkZDcmZrUC1KbzM0cmpUYXZwN1ByamVyb2gtb1BTWWc?oc=5" target="_blank">ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C</a>  <font color="#6f6f6f">The Cardiology Advisor</font>

Read Full StoryMore like this
New Expert Consensus Decision Pathway Addresses Use of Newer Nonstatin Therapies For Managing LDL-C in ASCVD Patients
American College of Cardiologygeneral

New Expert Consensus Decision Pathway Addresses Use of Newer Nonstatin Therapies For Managing LDL-C in ASCVD Patients

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQZWRWQnppbGVvM1N0VU9yWmx6ekdybGhxd0pFM1liSUkwdWFmQmNPS0tWX1lYd2dsblZWOWFjZFUtRWprRmtJeEtGRkpJNUY5VjM5R2o0NXBENndBT3RUUFNaelctRzFDSlRncktnYUxXX1BJNU5FTER3TFVONWt3RTJXX0k3cTVZd1dWNXF0S0hXNE51NlVFem5hVlVjY2ZrX2M3YTdIS2hGbGtaQ1RUTC1BVWE3UkQwNnhkTm5scG03ZnEtOXNpZ2VseUJ5dElXMWNqTDVaNTdQT2dnbUhXLVJkZ3JVQUtqMmRv?oc=5" target="_blank">New Expert Consensus Decision Pathway Addresses Use of Newer Nonstatin Therapies For Managing LDL-C in ASCVD Patients</a>  <font color="#6f6f6f">American College of Cardiology</font>

Read Full StoryMore like this
Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients
American Heart Association Journalsworld

Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1LWVdaTEJVQXRCdEgzRWZvZmRRTzhFWTlicnlrSnh5MXQtajNFV2hGekxQVkNiblZCNGEzN211TWQ5SXliaXp2cFZlOXVOSmx3X3BwYVowN3c5QkF3dzNKdGFFS0tfOXRVaENpOGZTR2U?oc=5" target="_blank">Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience
Frontiersgeneral

The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPRWE5YWp0SjdNdWJLV2Y2NmliRDZQMlQzdkRWOTh2ci1ySGJxVHlKcGo5N1RIX3k0czNRQldxZzNYcTdhQTdubmlOUHlob3lQb0U1Q3hwTFFqRi11MUdqMDJON2dnNUtPbGVLTktwbWdGSEJUU2IyWUVnR29kQkMzM3pLaERhQTZFV25uSXl1anZtMmRfNDBVQTY3a1VNVllUN2c?oc=5" target="_blank">The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines
JACC Journalsgeneral

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFB1elJXdW12UEVlX0pWN2IyVm9DbWFZUHdqYWE2c1B6OWlySVJyemY4ZWZldHNPMk9CbXVtTWxwXy0yRWczZWJqdlQzeF8wN2lkODFhUDcxbjljM0dCVm9aWg?oc=5" target="_blank">Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines</a>  <font color="#6f6f6f">JACC Journals</font>

Read Full StoryMore like this
Nonstatin Lipid-Lowering Therapies in Clinical Practice
Medscape Reference: Drugs, Diseases & Medical Proceduresgeneral

Nonstatin Lipid-Lowering Therapies in Clinical Practice

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxONlNMMTdFLTlOSHQtamlFWm5wYVdMdi0yZlg0VUZ0NXE4aU5qNEJoNzdDSG80YUpTX0RMMFhaaEpxNG43UmhnQ2Y0ZVIzWnpfaThXbXkxNGtDTzRRQmRrQnVDc2gyckZwTzZ0MDQzMkZVWjFQQjRmeW42QTNuR0lOczlBZVE1OTFqUUtIOXpfZnFJVTlJQ0Y1X2h3T3F6ZmVrRnlaSk1wZUJzbU5WbU45NE1B?oc=5" target="_blank">Nonstatin Lipid-Lowering Therapies in Clinical Practice</a>  <font color="#6f6f6f">Medscape Reference: Drugs, Diseases & Medical Procedures</font>

Read Full StoryMore like this
Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
American Heart Association Journalsgeneral

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE8yUjBXOEFTdEdfZmNUckxpVmJLbkcwRHZyU1RHS0RSWGxJeVk4VC1qS2dEaVd0OWg1TVhwYnpzdW82SU41bWJjbENYLV9xRXJMbHlLOXZvQmstbzNOTHA4anFGUHduQQ?oc=5" target="_blank">Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia
American College of Cardiologygeneral

ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOelE3Z1ZhRURpTW5tMjZLcjhmdEo1NnpCZ21WdGdEampTbUxSTHlGY0dpRHBuOFFRaFBLU3VKeWg1MGltNHQzdzIxOERGYnUxdWFXWlk1RFBVOF9hOFI5QU5RbmNpdW95bmhZQkU2bFVUVFN0OVM3M0pyMmlIajd3b0Z2akhaY2pkemROQ29Ga09yWkxKOWE2NVNRd01Bbm9XZENseHBZbVNXR1ZyX18xbmMyY2xKajRQY2d0RkJjczhBeXVBcEx4UXFMeWZrZDhPdWc?oc=5" target="_blank">ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia</a>  <font color="#6f6f6f">American College of Cardiology</font>

Read Full StoryMore like this
2022 ACC Consensus on Role of Nonstatin Therapies for LDL-Cholesterol Lowering
Pharmacy Timesgeneral

2022 ACC Consensus on Role of Nonstatin Therapies for LDL-Cholesterol Lowering

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxORWpJYTBRc0hCQmVSMkNtRUQxQXFaNnVUQ21OMzhiWEhhN2dnVzJNcF90QVFYaGNLSHE4dUhCdU1vb2FkaUZmY1dKTFIta3NWaXVMcTUzbjY5U0pvbG5STGdndVc4RWxKRG9FOG9scmhRR3NGWmhseDZTTnk5RlozOF9jRm5lNmZmSV9kSTJsMk10OHQwemZld1VUanUtUU5sVmNxOXh5OEVlVUpjNFBNZm04Yw?oc=5" target="_blank">2022 ACC Consensus on Role of Nonstatin Therapies for LDL-Cholesterol Lowering</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
How to Select Between Available LDL-C Lowering Therapies
HCPLivetech

How to Select Between Available LDL-C Lowering Therapies

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQeUkzY2EwanpGb0RURTRFbnRvQkhBSDB3VFNBUnVyazJicmhSS196Y2YtcGY1a0ZXLU1uRXF4QUl1UVdsLTdkSk5iVTNfTGUzRUJYQlR2TzhoTXdXYWFYODl5WGgtUmlucjJUclpCT0pLb1lCODR6ZlR2WEkwS1l3NEo0Y1Z0eExsUXRXOFJn?oc=5" target="_blank">How to Select Between Available LDL-C Lowering Therapies</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Mechanism of Action of Nonstatin Therapies
HCPLivegeneral

Mechanism of Action of Nonstatin Therapies

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE94dXkxSmRTMjZpOFRjSmNZRnhPbnRHMnRCTWhiaWRYaDVGdjZfVnFoSm5SZGxWa3h6aEJ5eXNDOFNXd3RGaXpELUVWZG9FUnc4THlLUTcxTmFCS3ViUkVfVldTdnQ4Y0lMMktSZ2xBX0dGVUhPVFVyVm8xOA?oc=5" target="_blank">Mechanism of Action of Nonstatin Therapies</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Novartisworld

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

<a href="https://news.google.com/rss/articles/CBMiwgJBVV95cUxQeDNhcnlVVVRTOEJHWE1FVU5iaFJPc2c4NXRGVFJaTVRxbl9mVzZFeWpJclo5a2NIZmlTM3Y1R3JFY0dxYk54R3JHay1kSlE4dk9aeXNtNlFnOVN5X0NUWGRGR3RSLVpvZmIwLUk0S2dZYjdja284Nzdra3JhVEVPMTJwc2tOdXExYlJCTFVtUFNsVzlsUDl5ZThoUFZOXzE4M0luNGNLV3BtcDhxWGdqTXMtaEtPUy0zYmhaZTRnM2lubFFBbzdnQ2hnOE1HUWxjcjdfcFBLZDFCRFdyakZGN3ZvZF9KUWxTR2hiZXF4eTFpNFBpaGtYaDVaV1dQclM1Q3E0OWw1WVh2VUwxaF9TY1paY0ZYZ3lkdDJWY3dFN0xmaF9SMnZEeVFQWTM4R2NMbnRwQUZxT2hmbmkyZGdYVXRB?oc=5" target="_blank">New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting</a>  <font color="#6f6f6f">Novartis</font>

Read Full StoryMore like this
New Guidance in Lowering LDL-C
HCPLivegeneral

New Guidance in Lowering LDL-C

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE9HS0toZTVOTlZEX0tCeXdlUXctX2JGRzFOZGdadWxJdmZKNVdVSnhQXzhtZS1STkJBMU5jQmJiVlBsc2lSWlUwRG56LW96RnRYU0ltd2JlellzOGFuLXdxaF96eWMyUmltZEk0?oc=5" target="_blank">New Guidance in Lowering LDL-C</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
The Cumulative Burden of LDL-C
HCPLivegeneral

The Cumulative Burden of LDL-C

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE1laU8tNkczMW8zT25qeXFtM0h4Mm5FMEk1U05Pd05oa1llSWotcjRMWmhFMXBrNDZjUVhVamlWOFU0aGo0QlFra2RjdGEyYTlyRGVINHdneVZGRFpnTkdid1FzYVRHdUlnSVZB?oc=5" target="_blank">The Cumulative Burden of LDL-C</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
The Case For Earlier LDL Cholesterol Lowering: Supporting Lifelong Healthy Vascular Aging
American College of Cardiologyscience

The Case For Earlier LDL Cholesterol Lowering: Supporting Lifelong Healthy Vascular Aging

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQTWJZNjdIbF96TmhxZUV1dDJoSUFuMElkYnRqY0J2Q09oTnpjcGpjWUd2TVk5UDlMNHRGYXdKam9zenpHZXRWMEh1LWZwRFdWd2RoVmlRNmY1cVRlWXhYUG1obG1iMzU2eGZzMTJzYTlsb1JOZHM4YlA3Z3o4MUx1WEVJbEhnaldNWVdxWV9VYWZkRUJCUXJNdnp2Mk1FQzBsVy1Wd0FOd0pUNTliVlRSMFpn?oc=5" target="_blank">The Case For Earlier LDL Cholesterol Lowering: Supporting Lifelong Healthy Vascular Aging</a>  <font color="#6f6f6f">American College of Cardiology</font>

Read Full StoryMore like this
Inclisiran Plus Usual Care Enhances LDL-C Control Post Acute Coronary Syndrome
Pharmacy Timesgeneral

Inclisiran Plus Usual Care Enhances LDL-C Control Post Acute Coronary Syndrome

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNcmsxNUxZU1RCWXNyRjhQSVhfTWMyU3RpS19Kc0M2MW16MUZUbVR0TjlTSlQ4dTQxVGF1ZXVhWkhYUUFESklrc2NNVFF3R1pYSFp6c3l6bDRvYzgxX1JZZm1DeklocXVjSzlWazlIcVlOQXh6ODIwZUI2clc5TFF5T1dGcjQ2cFFJMEVOTkR0MnNvdlcyYThhTXQ2WjFQVC04UFZoazcwaW15UDVEQ053RVp1dw?oc=5" target="_blank">Inclisiran Plus Usual Care Enhances LDL-C Control Post Acute Coronary Syndrome</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients
HCPLivegeneral

Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOWFltSHFYZW9LaHdfYm9KM012bzFhNTRoZEdyVUp6c0paUV9wbXJ0bnFLM3IwTlJUWjhuZmo1WU1QS2dHZ2pmc2pNQ2JuY2VtYWVlZVo4OW5nUUU3M194MnNLUjBwb2IwcnAyQlNoWWdHa3l1Z1ladlFjbjBwaEtuMkJ0UE1QVlBSei1hV2FvUF94aUlLbzZzbEZRamJ0Y2Q1dHlLc01TV0c?oc=5" target="_blank">Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Study finds major gaps in cholesterol management among adults with cardiovascular disease
News-Medicalgeneral

Study finds major gaps in cholesterol management among adults with cardiovascular disease

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPeHZJSW4yOU13RHhlSjZBd3hjb0ZUX0dncWxWRzZQMTFReVhiMklNeHlsck9YOTJFclh6VVQ5ZzJsVTJOSm42eTAzR0VfaURBZGpVLVlwZG1RbG4yeTVKZ0V2NWdhN3BOWllhYXVQQWdoQ2YyS1IyQWhabWZwR0R5cWdFSkd2dEhPdFB4Y1RTejVvQ2NjYjNTYnBGWG04SlF5ZFFybmFpb1hSelQwQnpjczE0Yzh6emZyb3lDblBKTzVSMzJzX3FhOVpJcnk4NU9sNkNF?oc=5" target="_blank">Study finds major gaps in cholesterol management among adults with cardiovascular disease</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
Statin Intolerance and New Lipid-Lowering Treatments
Cleveland Clinicgeneral

Statin Intolerance and New Lipid-Lowering Treatments

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOSFJZVGRZNEFoNGNFUHpOcGJFSnAtVlI0MmZTcnFIRmp6bU9rcTM4X2JzOTVPSElmbWtnVEg4UHJMTGNtdmI5a2NJU0dGaHZ5SGdQVVBoYVJDejlYOHRGVTU2Y2VrLW5ZYVhOV0hHSVc0NXp0MHlKSWY5My1FNEFhSUFjR1hyWFEtZzM5aWE1MWYzMEFV?oc=5" target="_blank">Statin Intolerance and New Lipid-Lowering Treatments</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
Network Meta-Analysis Details Comparative Efficacy of Nonstatin Lipid-Lowering Agents
HCPLivetech

Network Meta-Analysis Details Comparative Efficacy of Nonstatin Lipid-Lowering Agents

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQOUN1eVcycV9jQ3J6ZWhlVVdiSmJNNDJoWWplMVVLRUUybXZOa0U1bG1KbTJTSTRTWlZVc1NIcVljODV6QWptZV94UTkwck1kV0ppbTEtM0pZdVhwNlRyanU1a19Ta0oxMzZmZEwwRUphLVZKekdxalF3dlpIVWE3ckw2azdjWDNSWWRhcEg0R25YejNFdWlVUXZHZ2VaWVctQWo4SnRWMG9UV3NKZHE5UXkyNW4?oc=5" target="_blank">Network Meta-Analysis Details Comparative Efficacy of Nonstatin Lipid-Lowering Agents</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies
Pharmacy Timesgeneral

Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNMkJHQ2lfeVliUUd2RThNVnVhcE5WTjk1R1A5bDRRRUx1RXNGdnVwdGFNWGZlQmNhZkJaVlZaWUV0X21pMlI4NzdQYnFxN2RuX1lzWnNSbDFoZjJtVHhkcTREaHZpSXItZFJxMWhVbjBkYzYxb0s4WkZVVm5iMHF5d3Vrdjd5RkFJdGIzOEdXNHVkQkZIUnhfTjg4QmVKQ0theHNhT2s2VQ?oc=5" target="_blank">Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
"How Nonstatin Therapies C" — Live Google News Trends & Headlines